Gestational trophoblastic neoplasia differential diagnosis: Difference between revisions

Jump to navigation Jump to search
Mmir (talk | contribs)
Mahshid
Skazmi (talk | contribs)
No edit summary
Line 15: Line 15:
* [[Ectopic pregnancy]]  
* [[Ectopic pregnancy]]  
* Normal term [[pregnancy]]
* Normal term [[pregnancy]]
 
{| class="wikitable"
|+
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Clinical Features
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Complete Hydatidiform Mole
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Partial Hydatidiform Mole
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Invasive Molar Pregnancy
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Choriocarcinoma
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Placental-site trophoblastic tumor (PSTT) and Epithelioid trophoblastic tumor (ETT)
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Presenting Complaints'''
|
* [[Vaginal bleeding]]
* Inappropriately large for date [[uterine]] size
* [[Hyperemesis]]
|
* [[Vaginal bleeding]]
|
* [[Vaginal bleeding]]
* Elevated [[Human chorionic gonadotropin|beta-hCG]]
|
* [[Vaginal bleeding]]
|
* [[Vaginal bleeding]]
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Neoplastic Conversion'''
|
* High rate of progression (15-20%)
|
* < 5 % progression rate
|
* [[Neoplastic disease|Neoplastic]]
|
* [[Neoplastic disease|Neoplastic]]
|
* [[Neoplastic disease|Neoplastic]]
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Beta Human Chorionic Gonadotropin (Beta-hCG) baseline levels'''
|
* Extremely high levels ( > 100000 mIU/ml in half of the patients
|
* Highly elevated ( > 100000 mIU/ml in one in ten patients)
|
* High
|
* High
|
* Moderatley elevated (< 1000 mIU/ml in majority of patients)
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''History of Pregnancies'''
|
* Not related
|
* Not related
|
* Consequence of [[Hydatidiform mole|molar pregnancy]]
|
* Approximately half of the cases occur as a consequence of [[molar pregnancy]]
* Quarter of the cases follow [[abortion]] or [[tubal pregnancy]]
* Rest follow term or [[Preterm|pre-term pregnancy]]
|
* About 60% follow term pregnancy
* 40 % follow [[molar pregnancy]] or [[abortion]]
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Metastatic Route'''
|
* [[Benign]]
|
* [[Benign]]
|
* [[Blood|Hematogenous]]
|
* [[Blood|Hematogenous]]
|
* [[Lymphatic system|Lymphatic]]
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |'''Management'''
|
* [[Dilation and curettage (patient information)|Dilation and curettage (suction)]]
|
* [[Dilation and curettage (patient information)|Dilation and curettage (suction)]]
|
* [[Chemotherapy]] ([[Methotrexate]])
|
* [[Chemotherapy]] ([[Methotrexate]])
|
* [[Hysterectomy]]
|}
==References==
==References==
{{reflist|2}}
{{reflist|2}}

Revision as of 15:16, 28 February 2019

Gestational trophoblastic neoplasia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Gestational trophoblastic neoplasia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Gestational trophoblastic neoplasia differential diagnosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Gestational trophoblastic neoplasia differential diagnosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Gestational trophoblastic neoplasia differential diagnosis

CDC on Gestational trophoblastic neoplasia differential diagnosis

Gestational trophoblastic neoplasia differential diagnosis in the news

Blogs on Gestational trophoblastic neoplasia differential diagnosis

Directions to Hospitals Treating Gestational trophoblastic neoplasia

Risk calculators and risk factors for Gestational trophoblastic neoplasia differential diagnosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Monalisa Dmello, M.B,B.S., M.D. [2]

Overview

Choriocarcinoma must be differentiated from non neoplastic diseases, neoplastic diseases, and other causes of bleeding during pregnancy.

Differentiating choriocarcinoma from other diseases

Choriocarcinoma must be differentiated from other non-neoplastic diseases such as:

Choriocarcinoma must be differentiated from other neoplastic diseases such as:

  • Invasive hydatidiform mole
  • Placental site trophoblastic tumor (PSTT)
  • Mixed germ cell tumor - esp. for testicular and ovarian tumors

Choriocarcinoma must be differentiated from other causes of bleeding during pregnancy:

Clinical Features Complete Hydatidiform Mole Partial Hydatidiform Mole Invasive Molar Pregnancy Choriocarcinoma Placental-site trophoblastic tumor (PSTT) and Epithelioid trophoblastic tumor (ETT)
Presenting Complaints
Neoplastic Conversion
  • High rate of progression (15-20%)
  • < 5 % progression rate
Beta Human Chorionic Gonadotropin (Beta-hCG) baseline levels
  • Extremely high levels ( > 100000 mIU/ml in half of the patients
  • Highly elevated ( > 100000 mIU/ml in one in ten patients)
  • High
  • High
  • Moderatley elevated (< 1000 mIU/ml in majority of patients)
History of Pregnancies
  • Not related
  • Not related
Metastatic Route
Management

References